Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Market Approval On Track For All-Case Surveillance Drugs From Lilly, GSK, Otsuka

This article was originally published in PharmAsia News

Executive Summary

TOKYO - A string of drugs are on track for marketing approval in Japan, as the pharmaceutical subcommittee of the Pharmaceutical Affairs and Food Sanitation Council confirmed its consent for approval of 22 new drugs and additional indications

You may also be interested in...

NICE Rejects Revolade For Bleeding Disorders; GSK Considering Its Options

UK's cost effectiveness watchdog is uncertain about Revolade's long-term effects and cost

Japanese Ministry Recommends Approval For J&J, GSK Drugs; Takeda Actos/Alogliptin Combo Missing

Japan's Ministry of Health, Labor and Welfare has recommended 10 drugs for marketing approval; these include new drugs from Johnson & Johnson, Eli Lilly, GlaxoSmithKline and Nippon Medi-Physics

Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis

Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts